Ezharmia Tablet Post-marketing Surveillance
Active, not recruiting
- Conditions
- Relapsed or refractory Adult T-cell leukemia/lymphoma (ATL)
- Registration Number
- jRCT2031220503
- Lead Sponsor
- Daiichi Sankyo Co.,Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
All patients who start receiving Ezharmia Tablet during the registration period.
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method - Cumulative incidence of AEs (safety specifications of the survey and other AEs)
- Secondary Outcome Measures
Name Time Method